doi: 10.1016/S0140-6736(19)31149-3 43 ChenYHHuangCNChoYMLiPGuLWangFet al
[1] [2] These medicines include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro), which is a dual GIP/GLP-1 receptor agonist
While this body of evidence is highly encouraging, it is important to note that these findings are derived from studies with considerable methodological heterogeneity, a limitation that will be addressed in the Discussion
GLP-1RAS IN OSTEOARTHRITIS Osteoarthritis (OA) is a degenerative joint disease characterized by progressive degradation of the cartilage cushioning the ends of bones, subchondral bone remodeling, and synovial inflammation, leading to joint stiffening and decreased motility[7]